An experimental immune-modulating therapy called KROS 101 was able to activate immune cells to kill glioma cells in laboratory experiments, according to new preclinical…
News
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Gradalis’ experimental immunotherapy platform Vigil (Gemogenovatucel-T) as…
A first patient with relapsed/refractory multiple myeloma (RRMM) treated with CT0590, Carsgen Therapeutics’ CAR T-cell therapy, showed a complete response to the…
Treatment with the cancer vaccine galinpepimut-S (GPS) is showing promise to potentially improve survival in people with acute myeloid leukemia (AML), a type of…
Certain immunotherapies may be effective in some cases of pancreatic neuroendocrine neoplasms (Pan-NEN), a rare type of pancreatic cancer, according to a study that…
The Lundin Cancer Fund has donated $4 million to the Canadian Cancer Society to create the Glioblastoma Research Program, a five-year initiative to…
About a third of women with cyclin E1+ platinum-resistant ovarian cancer (PROC) responded to treatment with azenosertib, an experimental therapy by Zentalis. That’s according…
Researchers in Brazil have developed a large dataset of cells taken from the bone marrow of people with multiple myeloma (MM) and other blood…
The European Commission has approved Blincyto (blinatumomab) as part of a consolidation therapy regimen to reduce the risk of relapse in adults newly diagnosed…
Treatment with the once-daily oral therapy lixumistat, in addition to chemotherapy, slowed the growth of pancreatic cancer among participants with advanced disease in an…
